Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

926 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-06-30

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective observational cohort study will assess the average duration of the drug free interval between etanercept treatment cycles in usual care settings in Germany.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Evaluating Enbrel (Etanercept) in Adult Patients With Plaque Psoriasis

NCT00227240

Plaque Psoriasis

COMPLETED

Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis

NCT00333034

Psoriasis

COMPLETED PHASE3

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel

NCT01891864

Chronic Stable Plaque Psoriasis

COMPLETED PHASE3

Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis

NCT00663052

Plaque Psoriasis Psoriasis

COMPLETED PHASE4

Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis

NCT00332332

Psoriasis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Non-interventional study: subjects to be selected according to the usual clinical practice of their physician

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Patients with moderate to severe plaque psoriasis

etanercept (Enbrel®)

Intervention Type DRUG

The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

etanercept (Enbrel®)

The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects with moderate to severe plaque psoriasis on etanercept treatment according to the Summary of Product Characteristics (SmPC), and applicable local guidelines
* Subjects for whom the decision has already been made to initiate treatment with etanercept

Exclusion Criteria

* Sepsis or risk of sepsis
* Current or recent infections, including chronic or localized, e.g. tuberculosis (TB) infection
* Vaccination with live vaccine in last 4 weeks, or expected to require such vaccination during the course of the study
* Pre-existing or recent onset CNS demyelinating disease.
* Class III or IV congestive heart failure as defined by the New York Heart Association classification or uncompensated congestive heart failure.
* Previous or ongoing treatment with etanercept
* Participation in other clinical or observational studies.
* Patients with psoriatic arthritis requiring continuous etanercept treatment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No